Senores Pharmaceuticals Ltd
SENORES NSE
Senores Pharmaceuticals Ltd
HealthcareNSE: SENORES BSE: 544319 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹7,070 Cr
Volatility
High Risk
P/E Ratio
56.05
EBITDA
₹168 Cr
Return on Equity
7.18%
Debt to Equity
0.37
Book Value
₹202.72
52W High
₹1,549.8
52W Low
₹662.45
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Senores Pharmaceuticals Ltd insights
41 extracted metrics + investor summaries across FY22–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company is expected to give good quarter
Weaknesses
6- Stock is trading at 7.62 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 13.9% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 187 days.
- Working capital days have increased from 67.9 days to 132 days
Growth Rate
Revenue Growth
51.53% ↗
Net Income Growth
138.70% ↗
Cash Flow Change
-78.68% ↘
ROE
-49.15% ↘
ROCE
1.63% ↗
EBITDA Margin (Avg.)
-5.13% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 42d agoAI opinion · based on fundamentals
Risk high
Senores Pharmaceuticals trades at a market cap of ₹6,358 Cr with a PE of 52.3x and has delivered exceptional top-line growth of 162% CAGR over 3 years, but carries concerns around working capital efficiency with debtor days at 187 and no dividend payouts despite consistent profitability.
Bull Case 7
- Compounded sales growth of 162% CAGR over 3 years indicates rapid revenue scale-up in the pharmaceutical space
- TTM sales growth of 59% demonstrates continued strong momentum even on a larger base
- Compounded profit growth of 139% CAGR over 3 years outpaces many pharma peers significantly
- TTM profit growth of 97% shows accelerating bottom-line expansion year-over-year
- Stock has delivered 144% returns over 1 year reflecting strong market confidence in the business trajectory
- Company is expected to deliver a good upcoming quarter based on operational momentum
- Consistent ROE of 13-14% over the last 3 years indicates stable profitability despite rapid growth phase
Bear Case 8
- Debtor days at 187 days is extremely high, indicating potential collection challenges or channel-stuffing risk
- Working capital days have deteriorated sharply from 67.9 days to 132 days, straining cash flows
- PE ratio of 52.3x is expensive relative to broader pharma sector averages of 25-35x, leaving limited margin of safety
- Price-to-book of 6.81x is elevated for a company with ROE of only 13.9%, implying premium valuation not fully justified by returns
- Zero dividend yield despite reporting repeated profits suggests cash is being retained without clear capital allocation policy
- ROE of 13.9% over 3 years is below the 15-20% threshold typically expected for quality pharma compounders
- Possible capitalization of interest costs may be flattering reported profitability relative to true operating performance
- Limited long-term track record with no available 5-year or 10-year growth data makes durability of growth difficult to assess
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 42d ago Headwinds 3
- IPO proceeds utilisation change sought Jul 4
Company seeks shareholder approval to vary utilisation of ₹650.16 million in unutilised IPO proceeds, raising questions about original capital allocation plans.
- Large related party transactions Jul 4
Seeking approval for material related party transactions aggregating ₹754 crore and enhanced limits for loans/guarantees under Sections 185 and 186.
- Company Secretary relieved Jun 10
CS Vinay Kumar Mishra relieved from duties effective June 10, 2026, with MD and CFO now handling disclosures directly.
Neutral 3
- Postal ballot voting opens Jul 4
Voting on IPO proceeds variation and RPT approvals runs from July 5 to August 3, 2026.
- Analyst meet in Ahmedabad Jul 1
Group meeting for analysts and investors scheduled for July 7, 2026, in Ahmedabad using publicly available information.
- Virtual investor conference Jun 9
Virtual investor conference hosted by Choice Broking held on June 12, 2026, relying on publicly available information.
TL;DR: Senores Pharmaceuticals is in a governance-heavy phase with no operational positives reported. The proposed variation of ₹650.16 million in IPO proceeds and ₹754 crore in related party transactions warrant investor scrutiny on capital discipline. The departure of the Company Secretary adds mild uncertainty. The near-term outlook depends on shareholder approval outcomes by August 3 and clarity on how redirected funds will be deployed.
Quarterly Results
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 102 | 80 | 101 | 103 | 114 | 138 | 162 | 171 | 175 | 180 |
| Expenses | 64 | 80 | 59 | 77 | 77 | 95 | 104 | 112 | 121 | 128 | 126 |
| Operating Profit | 15 | 22 | 21 | 23 | 26 | 19 | 34 | 50 | 50 | 47 | 54 |
| OPM % | 19% | 22% | 27% | 23% | 25% | 17% | 25% | 31% | 29% | 27% | 30% |
| Other Income | 1 | 2 | 0 | 2 | 5 | 12 | 3 | 5 | 7 | 18 | 3 |
| Interest | 2 | 3 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 8 | 7 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 8 | 9 | 10 |
| PBT | 10 | 18 | 13 | 16 | 20 | 21 | 26 | 41 | 45 | 47 | 39 |
| Tax % | 31% | 19% | 19% | 18% | 20% | 13% | 20% | 26% | 25% | 23% | 23% |
| Net Profit | 7 | 14 | 11 | 13 | 16 | 18 | 21 | 30 | 34 | 37 | 30 |
| EPS in Rs | 2.37 | 5.23 | 3.23 | 3.86 | 3.73 | 3.87 | 4.28 | 7.03 | 6.87 | 6.86 | 6.67 |
Profit & Loss
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 14 | 35 | 215 | 398 | 633 | 688 |
| Expenses | 12 | 23 | 173 | 309 | 464 | 487 |
| Operating Profit | 2 | 13 | 42 | 90 | 168 | 201 |
| OPM % | 14% | 36% | 19% | 23% | 27% | 29% |
| Other Income | 0 | 4 | 3 | 19 | 47 | 33 |
| Interest | 1 | 2 | 9 | 22 | 25 | 27 |
| Depreciation | 1 | 2 | 10 | 17 | 31 | 35 |
| PBT | 1 | 12 | 25 | 71 | 159 | 172 |
| Tax % | 13% | 32% | -31% | 17% | 24% | — |
| Net Profit | 1 | 8 | 33 | 58 | 122 | 131 |
| EPS in Rs | 1.01 | 8.59 | 10.31 | 12.72 | 25.05 | 27.43 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 31 | 46 | 46 |
| Reserves | 28 | 36 | 174 | 740 | 888 |
| Borrowings | 15 | 63 | 258 | 315 | 342 |
| Other Liabilities | 8 | 23 | 160 | 126 | 328 |
| Total Liabilities | 59 | 131 | 622 | 1,227 | 1,604 |
| Fixed Assets | 7 | 27 | 235 | 301 | 755 |
| CWIP | 8 | 34 | 97 | 172 | 17 |
| Investments | 15 | 16 | 0 | 0 | 4 |
| Other Assets | 29 | 53 | 289 | 754 | 827 |
| Total Assets | 59 | 131 | 622 | 1,227 | 1,604 |
Cash Flow
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Operating | -10 | -1 | -26 | -46 | 62 |
| Investing | -24 | -48 | -54 | -429 | -121 |
| Financing | 36 | 46 | 87 | 573 | -1 |
| Net Cash Flow | 2 | -3 | 8 | 98 | -60 |
| Free Cash Flow | -21 | -48 | -78 | -203 | -203 |
| CFO/OP | -526 | 3 | -56 | -41 | 45 |
Ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 506 | 228 | 191 | 114 | 187 |
| Inventory Days | 135 | 89 | 184 | 232 | 130 |
| Days Payable | 324 | 388 | 556 | 275 | 340 |
| Cash Conversion Cycle | 317 | -71 | -182 | 70 | -24 |
| Working Capital Days | 359 | -7 | -16 | 88 | 132 |
| ROCE % | — | 18% | 12% | 11% | 15% |
Documents
1
Board Meeting Intimation for Considering And Approving The Audited Consolidated And Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And To Transact Other Business Matters
8 May - Board meeting on May 14, 2026 to approve FY26 audited standalone and consolidated results. 8 May - Board meeting on May 14, 2026 to approve FY26 audited standalone and consolidated results.
2
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 May - Senores Pharmaceuticals will hold Q4FY26 earnings call on May 14, 2026 at 5:00 P.M. IST. 8 May - Senores Pharmaceuticals will hold Q4FY26 earnings call on May 14, 2026 at 5:00 P.M. IST.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
29 Apr - Senores Pharmaceuticals confirms it is not a Large Corporate; outstanding borrowing was Rs 54.07 crore as of March 31, 2025. 29 Apr - Senores Pharmaceuticals confirms it is not a Large Corporate; outstanding borrowing was Rs 54.07 crore as of March 31, 2025.
4
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
29 Apr - Senores Pharmaceuticals confirms it is not a Large Corporate; outstanding borrowing was Rs 54.07 crore as of March 31, 2025. 29 Apr - Senores Pharmaceuticals confirms it is not a Large Corporate; outstanding borrowing was Rs 54.07 crore as of March 31, 2025.
5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Apr - Senores Pharmaceuticals Limited has informed regarding Certificate pursuant to Regulation 74(5) of SEBI (DP)Regulations,2018 for quarter ended March 31, 2026 6 Apr - Senores Pharmaceuticals Limited has informed regarding Certificate pursuant to Regulation 74(5) of SEBI (DP)Regulations,2018 for quarter ended March 31, 2026
Frequently Asked Questions about Senores Pharmaceuticals Ltd
What does Senores Pharmaceuticals Ltd do?
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
Where is Senores Pharmaceuticals Ltd (SENORES) listed?
Senores Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: SENORES and BSE: 544319. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Senores Pharmaceuticals Ltd belong to?
Senores Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd has a market capitalisation of approximately ₹7070.15 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Senores Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of Senores Pharmaceuticals Ltd is 56.05. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Senores Pharmaceuticals Ltd?
Over the past 52 weeks, Senores Pharmaceuticals Ltd has traded between a low of ₹662.45 and a high of ₹1,549.8. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd has a Return on Equity (ROE) of 7.18%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Senores Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view Senores Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]